SUBSCRIBE
SUBSCRIBE

Phase 3

Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
After Fraud Probe, Alexion Reports Failed Soliris Trial
December 22, 2016
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
The 7 Worst Clinical Disasters of 2016
December 22, 2016
 · 
4 min read
Ex-Akebia Director Re-arrested After Insider Trading Prosecutors Call Him Unhinged
Drug Development
Concordia Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index
December 19, 2016
 · 
3 min read
For Sale: Pfizer's $3.4 Billion Consumer Healthcare Business
Drug Development
Pfizer’s Xtandi Flunks Late-Stage Study Against Johnson & Johnson’s Zytiga
December 15, 2016
 · 
2 min read
Drug Development
3 Drugs Heading To The FDA Soon
December 12, 2016
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Ophthotech Plunges as Wet AMD Drug Combo Trials With Novartis AG Flops in Phase III Studies
December 12, 2016
 · 
2 min read
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Drug Development
3 Biotechs That Could Peak in 2017
December 9, 2016
 · 
3 min read
As Biogen's Drug Shines, Eli Lilly Releases Detailed Results of Its Own Failure Solanezumab
Drug Development
As Biogen’s Drug Shines, Eli Lilly Releases Detailed Results of Its Own Failure Solanezumab
December 9, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Investors Sigh With Relief as Biogen’s Alzheimer’s Drug Delivers in Early-Stage Study
December 9, 2016
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Horizon Pharma Craters as Rare Neuromuscular Drug Flunks Late-Stage Study
December 8, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
 · 
9 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Load More